Research

SINOPHARM (1099 HK)

Sinopharm is not the lowly geared, cash generative company it seems. Operating cash inflows have been entirely manufactured through two methods: First, trade creditor repayments have been reclassified from operating cash flows to financing activities…an accounting first. Second, the company has sold ever greater quantities of receivables. Adjust for this and there are no operating cash inflows while leverage is worryingly high. Add into the mix the pursuit of growth through acquisitions, reduced financial disclosure, management’s failure to address our concerns, and we believe that the stock is virtually uninvestable. For those wishing to short, there is likely at least…
Read more ›

Log In

Insights

IN BRIEF: CTRIP (CTRP US)

Cashflow confusion questions premium rating

Mark Webb · 7 December 2017

Online travel agency Ctrip has delivered remarkable revenue growth. Moreover, despite the cost of integrating new businesses, Ctrip’s free cash flow also appears to have improved, with rising reported operating cashflow and falling capex. However, rather than indicating robust health, Ctrip’s headline performance shows how easily investors can be misled by the cashflow statement. The cashflow is primarily designed to assess liquidity and omits payments made using debt and equity rather than cash. In the case of Ctrip, if we include significant outflows from share-based staff pay and share-funded acquisitions in 2014-16, performance deteriorates from a headline free cash inflow…
Read more ›

IN-BRIEF: CHINA HONGQIAO (1378 HK)

Unresolved Issues (SELL/AVOID/SHORT)

Nigel Stevenson · 29 November 2017

China Hongqiao’s post-suspension share price appreciation might lead some to believe that fraud allegations have been addressed, but we are not entirely convinced. Even if investors can accept that the company had four different auditors in two years, they still have to grapple with a less than satisfactory response to fraud allegations and a very worrying set of financial statements containing similar traits to past frauds. The stock might be trading on 5x 2018 PER (assuming profits are real) but we would still be sellers. The cost of shorting is expensive at 9% but might be a strategy for risk…
Read more ›

COMING UP SHORT

Manipulating cash flows

Mark Webb · 22 November 2017

Investors increasingly view the income statement as unreliable; instead modelling cash flows to gauge performance. But the cash flow statement is flawed from an investment perspective as it only aims to reconcile movements in cash. This means that purchases funded with debt or equity are excluded which can materially distort operating and free cash flows. In this report, we discuss the most common practices affecting cash flows and highlight those stocks most impacted, such as China Southern, JD.com, Ctrip.com, China Resources Pharma and CKH Holdings. GET PDF VIEW SLIDES Payments using debt Items paid directly with debt, rather than cash,…
Read more ›

Free Newsletter

GET OUR FREE NEWSLETTER

Input your email address below to sign-up to our free newsletter.